GlassScriptPhysician profile
Sindhu A Abraham
NPI 1033178223
$18,014.57
in general payments reported to CMS, 2019-2025
55 companies · $3,298 in 2025
The $3,298 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,266 · 2020: $665 · 2021: $1,756 · 2022: $2,220 · 2023: $4,683 · 2024: $3,127 · 2025: $3,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,636 · Consulting Fee: $2,375 · Travel and Lodging: $81.94 · Education: $14.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,636.00 |
| Consulting Fee | $2,375.00 |
| Travel and Lodging | $81.94 |
| Education | $14.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,746.03 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Ardelyx, INC. | $1,468.88 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $966.36 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $911.39 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $904.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Enterra Medical, INC. | $846.90 | 2023-2025 | |
| Celgene Corporation | $681.53 | 2021-2024 | Zeposia |
| Shire North American Group INC | $500.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $443.43 | 2019-2024 | Ocaliva |
| Pfizer INC. | $427.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $358.68 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Lilly USA, LLC | $355.96 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $344.34 | 2024-2025 | Iqirvo, Bylvay |
| Evoke Pharma, INC. | $324.97 | 2020-2025 | Gimoti |
| Genzyme Corporation | $322.99 | 2022-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $299.22 | 2021-2025 | Qsymia, Pancreaze |
| Ferring Pharmaceuticals INC. | $230.83 | 2019-2025 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $213.04 | 2022-2025 | Dupixent |
| Medtronic, INC. | $209.19 | 2022-2024 | Pillcam, Gi Genius |
| Ambu A/S | $200.00 | 2021 | |
| Madrigal Pharmaceuticals | $192.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Anx Robotica Corp | $182.10 | 2024 | |
| Phathom Pharmaceuticals, INC. | $181.64 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $181.23 | 2019-2025 | Livdelzi |
| Mauna Kea Technologies, INC. | $180.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $179.62 | 2022 | |
| Nestle Healthcare Nutrition INC. | $166.25 | 2023 | |
| Amgen INC. | $162.80 | 2020-2025 | Uplizna |
| Ethicon US, LLC | $156.98 | 2019-2024 | Linx Reflux Management System |
| Qol Medical, LLC | $147.54 | 2019-2025 | Sucraid, Sucraid |
| Abbott Laboratories | $142.30 | 2019-2022 | |
| Novo Nordisk INC | $119.35 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $110.33 | 2019 | |
| Celltrion USA INC. | $95.45 | 2023-2025 | Vegzelma, Yuflyma |
| Braintree Laboratories, INC. | $93.63 | 2019-2023 | Suflave |
| Shionogi INC | $93.22 | 2019 | |
| Alnylam Pharmaceuticals INC. | $93.17 | 2020-2024 | Oxlumo, Givlaari |
| Allergan, INC. | $84.63 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $82.86 | 2019-2023 | Linzess |
| Aimmune Therapeutics, INC. | $80.46 | 2023-2025 | Zenpep |
| Organon LLC | $76.70 | 2021-2025 | Hadlima, Renflexis |
| Medical Device Business Services, INC. | $76.15 | 2019 | |
| Daiichi Sankyo INC. | $53.13 | 2019-2021 | |
| Axonics, INC. | $48.69 | 2023 | Axonics |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.90 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $46.62 | 2021 | |
| Perspectum Diagnostics LTD | $43.39 | 2022-2023 | Livermultiscan |
| Neuraxis, INC. | $32.41 | 2025 | |
| Alfasigma USA, INC. | $31.94 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $19.84 | 2020 | |
| Portola Pharmaceuticals, LLC | $16.38 | 2019 | |
| Ucb, INC. | $13.96 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.07 | 2019 | |
| Covidien LP | $12.74 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,495.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.